Avacta Group

Avacta Group plc is a company that provides technologies, consumables, and reagents for the life sciences market, covering applications from drug discovery to diagnostics. The company leverages biophysical techniques to engage in the research, development, production, and delivery of instruments and services for the biopharmaceutical drug development and clinical diagnostics markets. Avacta is developing novel cancer immunotherapies by combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISION™ tumor-targeted chemotherapy. Through this approach, the company aims to address the lack of durable responses to current cancer immunotherapies and the high off-target toxicity experienced by most patients. Avacta aspires to become a leading provider of innovative next-generation diagnostic solutions and the preferred choice for disruptive immunodiagnostic products. Our diagnostics division is utilizing our proprietary Affimer® platform to develop AffiDX® in vitro diagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test.